2030 – Can TGF- β be a valuable marker for psychosis?
Role of cytokines has been widely investigated in schizophrenia. Previous data suggest that TGF- β pathways can be hyperactive in schizophrenia. Serum levels of TGF- β showed to be significantly increased in psychotic patients with first episode psychosis and schizophrenia in relapse. As a part of r...
Saved in:
Published in | European psychiatry Vol. 28; no. S1; p. 1 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier SAS
2013
|
Subjects | |
Online Access | Get full text |
ISSN | 0924-9338 1778-3585 |
DOI | 10.1016/S0924-9338(13)76960-8 |
Cover
Abstract | Role of cytokines has been widely investigated in schizophrenia. Previous data suggest that TGF- β pathways can be hyperactive in schizophrenia. Serum levels of TGF- β showed to be significantly increased in psychotic patients with first episode psychosis and schizophrenia in relapse. As a part of recently publish research, we try to establish if TGF- β can be a valuable marker for psychosis. We investigated psychotic patients, with first episode psychosis and schizophrenia in relapse (133 subjects) and healthy controls (36 subjects). Diagnoses were established using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). The psychopathological status of psychotic patients was assessed by trained physicians using Positive and Negative Syndrome Scale (PANSS). Serum level of cytokine was measured using sensitive enzyme-linked immunosorbent assay (ELISA). Binary logistic regression showed that increased level of TGF- β strongly correlated with presence of psychosis (OR 1.068 (1.015-1.123)). Analysis showed that TGF- β can be a valuable marker for psychosis (area=0.775, p<0.0005). The optimal cutoff value estimated for TGF- β that allows the discrimination of psychotic from non psychotic patients was 22pg/ml. For this cut-off we got sensitivity 70.4% and specificity 80.6%, i.e. this concentration of 22pg/ml TGF- β could have prognostic value. We envisage the possible role of TGF- β as a biomarker in preceding schizophrenia and showed that increased level of TGF- β enhanced the risk for psychosis. According to our results, TGF- β could be a valuable marker for schizophrenia. |
---|---|
AbstractList | Role of cytokines has been widely investigated in schizophrenia. Previous data suggest that TGF- β pathways can be hyperactive in schizophrenia. Serum levels of TGF- β showed to be significantly increased in psychotic patients with first episode psychosis and schizophrenia in relapse. As a part of recently publish research, we try to establish if TGF- β can be a valuable marker for psychosis. We investigated psychotic patients, with first episode psychosis and schizophrenia in relapse (133 subjects) and healthy controls (36 subjects). Diagnoses were established using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). The psychopathological status of psychotic patients was assessed by trained physicians using Positive and Negative Syndrome Scale (PANSS). Serum level of cytokine was measured using sensitive enzyme-linked immunosorbent assay (ELISA). Binary logistic regression showed that increased level of TGF- β strongly correlated with presence of psychosis (OR 1.068 (1.015-1.123)). Analysis showed that TGF- β can be a valuable marker for psychosis (area = 0.775, p < 0.0005). The optimal cutoff value estimated for TGF- β that allows the discrimination of psychotic from non psychotic patients was 22 pg/ml. For this cut-off we got sensitivity 70.4% and specificity 80.6%, i.e. this concentration of 22 pg/ml TGF- β could have prognostic value. We envisage the possible role of TGF- β as a biomarker in preceding schizophrenia and showed that increased level of TGF- β enhanced the risk for psychosis. According to our results, TGF- β could be a valuable marker for schizophrenia. Role of cytokines has been widely investigated in schizophrenia. Previous data suggest that TGF- β pathways can be hyperactive in schizophrenia. Serum levels of TGF- β showed to be significantly increased in psychotic patients with first episode psychosis and schizophrenia in relapse. As a part of recently publish research, we try to establish if TGF- β can be a valuable marker for psychosis. We investigated psychotic patients, with first episode psychosis and schizophrenia in relapse (133 subjects) and healthy controls (36 subjects). Diagnoses were established using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). The psychopathological status of psychotic patients was assessed by trained physicians using Positive and Negative Syndrome Scale (PANSS). Serum level of cytokine was measured using sensitive enzyme-linked immunosorbent assay (ELISA). Binary logistic regression showed that increased level of TGF- β strongly correlated with presence of psychosis (OR 1.068 (1.015-1.123)). Analysis showed that TGF- β can be a valuable marker for psychosis (area=0.775, p<0.0005). The optimal cutoff value estimated for TGF- β that allows the discrimination of psychotic from non psychotic patients was 22pg/ml. For this cut-off we got sensitivity 70.4% and specificity 80.6%, i.e. this concentration of 22pg/ml TGF- β could have prognostic value. We envisage the possible role of TGF- β as a biomarker in preceding schizophrenia and showed that increased level of TGF- β enhanced the risk for psychosis. According to our results, TGF- β could be a valuable marker for schizophrenia. |
ArticleNumber | 28-E1248 |
Author | Radosavljevic, G. Stefanovic, V. Lukic, M.L. Djukic Dejanovic, S. Jovanovic, I. Arsenijevic, N. Borovcanin, M. |
Author_xml | – sequence: 1 givenname: M. surname: Borovcanin fullname: Borovcanin, M. organization: Department of Psychiatry – sequence: 2 givenname: S. surname: Djukic Dejanovic fullname: Djukic Dejanovic, S. organization: Department of Psychiatry – sequence: 3 givenname: G. surname: Radosavljevic fullname: Radosavljevic, G. organization: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac – sequence: 4 givenname: I. surname: Jovanovic fullname: Jovanovic, I. organization: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac – sequence: 5 givenname: V. surname: Stefanovic fullname: Stefanovic, V. organization: Clinic for Mental Disorders ‘Dr Laza Lazarevic’, Belgrade, Serbia – sequence: 6 givenname: N. surname: Arsenijevic fullname: Arsenijevic, N. organization: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac – sequence: 7 givenname: M.L. surname: Lukic fullname: Lukic, M.L. organization: Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac |
BookMark | eNqNkE1KAzEUgINUsK0eQchSF6P5mUwyiBYptgoFF9Z1SDNvMO04U5K20J138CYexEN4EmdacVGQunqb932873VQq6xKQOiUkgtKaHL5RFIWRynn6ozyc5mkCYnUAWpTKVXEhRIt1P5dOUKdEKaEUElI0kaKEU7w19s77psSj4eDCH9-4Algg1emWJpJAfjV-Bl4nFcez8PavlTBhd4xOsxNEeDkZ3bR8-Bu3L-PRo_Dh_7tKLIs4SpSWcZ5TJgEoLFVkkmeigziOAMuRZwbIYBRJUWujIwBpFApU8QokrEktSnvIrH1Wl-F4CHXc-_qi9aaEt3k602-bto05XqTr1XNXe1w1i3MwlXlwhtX7KV7WxrqtJUDr4N1UFrInAe70Fnl9hpudgy2cKWzppjBGsK0Wvqy_pumOjBNtpLGQfnG0Aiu_xb844BvHqOcPQ |
CitedBy_id | crossref_primary_10_1038_s41598_024_73937_0 |
ContentType | Journal Article |
Copyright | 2013 Elsevier Masson SAS Elsevier Masson SAS |
Copyright_xml | – notice: 2013 Elsevier Masson SAS – notice: Elsevier Masson SAS |
DBID | AAYXX CITATION |
DOI | 10.1016/S0924-9338(13)76960-8 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1778-3585 |
EndPage | 1 |
ExternalDocumentID | 10_1016_S0924_9338_13_76960_8 S0924933813769608 1_s2_0_S0924933813769608 |
GroupedDBID | --- --K --M .1- .FO .~1 09C 09E 0R~ 1B1 1P~ 1~. 1~5 29G 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8FI 8FJ 8P~ AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AANRG AAOAW AAQXK AASVR AAXMD AAXUO AAYWO ABBQC ABBZL ABFNM ABGDZ ABIVO ABJNI ABMZM ABUWG ABVKB ABWVN ABXAU ABXDB ABXHF ACAJB ACDAQ ACDLN ACGFS ACHQT ACIUM ACQPF ACRPL ACVFH ACZWT ADAZD ADBBV ADCNI ADDNB ADEZE ADKIL ADMUD ADNMO ADOVH ADVJH ADVLN AEBAK AEKER AENCP AENEX AEUPX AEVXI AEYHU AFKRA AFPKN AFPUW AFRHN AFTJW AFZFC AGABE AGHFR AGJUD AGQPQ AGUBO AGYEJ AHIPN AHRGI AIGII AITUG AJPFC AJRQY AJUYK AKBMS AKMAY AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX AQJOH ASPBG AVWKF AZFZN AZQEC BENPR BLXMC BLZWO CCPQU CCQAD CCUQV CFBFF CGQII CJCSC CS3 DOHLZ DU5 DWQXO EBS EGQIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYUFA G-Q GBLVA GNUQQ GROUPED_DOAJ HVGLF HZ~ IHE IKXGN IOO IPYYG J1W LN9 M2M M41 MO0 N9A NZEOI O-L O9- OAUVE OH0 OK1 OU- OZT P-8 P-9 P2P PC. PHGZM PHGZT PIMPY PSYQQ PUEGO Q38 R2- RCA ROL RPM RPZ SCC SDF SDG SDP SES SEW SSZ UHS UKHRP UV1 WFFJZ Z5R ~G- 0SF AACTN AFCTW AJOXV ALIPV AMFUW NCXOZ RIG T5K AAEED AAQFI ABYKQ AEBPU AJBFU EFLBG LCYCR LW7 AAYXX CITATION |
ID | FETCH-LOGICAL-c2638-8dd334027ee14c8727395de44de3754fa55e21875f8a74ee7589280a80d269c93 |
IEDL.DBID | .~1 |
ISSN | 0924-9338 |
IngestDate | Thu Apr 24 22:51:53 EDT 2025 Tue Jul 01 05:33:28 EDT 2025 Fri Feb 23 02:25:06 EST 2024 Sun Feb 23 10:19:43 EST 2025 Tue Aug 26 16:31:41 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | S1 |
Language | English |
License | https://www.cambridge.org/core/terms |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c2638-8dd334027ee14c8727395de44de3754fa55e21875f8a74ee7589280a80d269c93 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1016_S0924_9338_13_76960_8 crossref_citationtrail_10_1016_S0924_9338_13_76960_8 elsevier_sciencedirect_doi_10_1016_S0924_9338_13_76960_8 elsevier_clinicalkeyesjournals_1_s2_0_S0924933813769608 elsevier_clinicalkey_doi_10_1016_S0924_9338_13_76960_8 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2013 2013-00-00 |
PublicationDateYYYYMMDD | 2013-01-01 |
PublicationDate_xml | – year: 2013 text: 2013 |
PublicationDecade | 2010 |
PublicationTitle | European psychiatry |
PublicationYear | 2013 |
Publisher | Elsevier SAS |
Publisher_xml | – name: Elsevier SAS |
SSID | ssj0017006 |
Score | 1.9880133 |
Snippet | Role of cytokines has been widely investigated in schizophrenia. Previous data suggest that TGF- β pathways can be hyperactive in schizophrenia. Serum levels... |
SourceID | crossref elsevier |
SourceType | Enrichment Source Index Database Publisher |
StartPage | 1 |
SubjectTerms | Internal Medicine Psychiatry |
Title | 2030 – Can TGF- β be a valuable marker for psychosis? |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0924933813769608 https://www.clinicalkey.es/playcontent/1-s2.0-S0924933813769608 https://dx.doi.org/10.1016/S0924-9338(13)76960-8 |
Volume | 28 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1778-3585 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017006 issn: 0924-9338 databaseCode: DOA dateStart: 19910101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1778-3585 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017006 issn: 0924-9338 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1778-3585 dateEnd: 20191001 omitProxy: true ssIdentifier: ssj0017006 issn: 0924-9338 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NS8MwGA5jB_EifuL8GDl40EO2Nk3b9CQynEOYFzfYLbRJCoM5xzqv4n_wn_hD_BH-Et-k6aY4GHgNedPy8H4m7wdCF4mWlEVhTmROGWHai0kWZ4wkYagVTRnEY6beuf8Q9YbsfhSOaqhT1cKYtEqn-0udbrW1W2k7NNuz8bj96JnQASIsH2QE_HBT8Gu6fwFPt16XaR6m_Zx9r4TNxOxeVfGUJ9jFSz-4socQvt4-_bA53V2045xFfFP-zx6q6ek-2uq75_ADBHY18PDX2zvupFM8uOsS_PmBM41TbJt4ZxONn0z-zRyDb4rLiqtiXFwfomH3dtDpETcKgUgKEkK4UkEAoV6stc8kN05HEirNmNJmhm2eArRgrOMw52nMtIYoIKHcS7mnaJTIJDhC9enzVB8jHEuZZHmQspQnjNI44ypkkpku3UCrggZiFQBCuj7hZlzFRKwSwgA3YXATfiAsboI3UGtJNisbZWwiiCp0RVUFCnpLgCrfRBivI9SFk75C-KKgwhN_OKSB-JLyF5Nt_ujJ_0lP0Ta1MzTMvc0Zqi_mL_ocPJlF1rSs2rT3AN_i6-dE |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LTsJAFL1BTNSN8RnxOQsXuhhop1M6XRlDRFRgIyTsJu10mpAgEopb4z_4J36IH-GXeKctoJGExO1kzrQ5uXMf7X0AnPtaMV51Y6pixinXlkdDL-TUd10dsYBjPGbqnVvtaqPL73turwC1aS2MSavMdX-m01Ntna9UcjYro36_8miZ0AEjLBvvCPrhYgVWuZEoFOry6yzPw_SfS39Y4m5qts_LeLIj0sUL27lMT6FisYH6YXTqW7CZe4vkOnuhbSjo4Q6stfL_4buAhtWxyNfbO6kFQ9K5rVPy-UFCTQKSdvEOB5o8mQScMUHnlGQlV0k_udqDbv2mU2vQfBYCVQyvCBVR5DgY63la21wJ43X4bqQ5j7QZYhsHyC1aa8-NReBxrTEM8JmwAmFFrOor39mH4vB5qA-AeEr5YewEPBA-Z8wLReRyxU2bbsRGTgn4lACp8kbhZl7FQM4zwpA3aXiTtiNT3qQoQXkGG2WdMpYBqlN25bQMFBWXRF2-DOgtAuokv36JtGXCpCX_iEgJxAz5S8qWP_Tw_9AzWG90Wk3ZvGs_HMEGSwdqmI84x1CcjF_0Cbo1k_A0FdtvGp3pbQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=2030+%E2%80%93+Can+TGF-+%CE%B2+be+a+valuable+marker+for+psychosis%3F&rft.jtitle=European+psychiatry&rft.au=Borovcanin%2C+M.&rft.au=Djukic+Dejanovic%2C+S.&rft.au=Radosavljevic%2C+G.&rft.au=Jovanovic%2C+I.&rft.date=2013&rft.pub=Elsevier+SAS&rft.issn=0924-9338&rft.volume=28&rft.spage=1&rft.epage=1&rft_id=info:doi/10.1016%2FS0924-9338%2813%2976960-8&rft.externalDocID=S0924933813769608 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F09249338%2FS0924933813X70142%2Fcov150h.gif |